Research Shows Gene-Based Test Can Prioritize Smokers For Lung Cancer CT Screening

Targeting highest risk smokers could make CT screening more cost effective, study finds

New research shows genetic test for lung cancer risk prompts smokers to quit

Philadelphia – November 8, 2010 – New research shows a gene-based test for lung cancer risk assessment motivates smokers to quit or cut down, according to results of a clinical study...

Synergenz BioScience Awarded Therapeutic Discovery Project Grant

Grant supports clinical utility studies for Respiragene™ lung cancer predisposition test

El Camino Hospital Respiragene Trial Video News Clip

Video news link explaining El Camino trial

AACR Feature: Genetic test may help target lung cancer CT screening (Healthimaging.com)

A gene-based test that estimates lung cancer risk may help identify which smokers are most likely to benefit from CT screening for lung cancer, according to a study presented at the American Association of Cancer Research (AACR) annual conference on Nov. 9.

El Camino Hospital Physicians Launch Trial (with RespirageneTM) to Find Early Diagnosis Tool for Lung Cancer (Enhanced Online News)

MOUNTAIN VIEW, Calif.--(EON: Enhanced Online News)--Physicians at El Camino Hospital are starting a medical trial called REACT that they hope may give doctors a new and cost-effective tool for early diagnosis of lung cancer, the deadliest of the common cancers.